Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
4.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
4.570
Bid (Size)
4.120 (1)
Ask (Size)
4.570 (2)
Prev. Close
4.570
Today's Range
4.570 - 4.570
52wk Range
1.690 - 4.680
Shares Outstanding
66,497,370
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Xeris Biopharma - Possibly The Best Pharma Stock
March 11, 2025
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.
Via
Talk Markets
Topics
Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
March 06, 2025
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.
Via
Stocktwits
Performance
YTD
+32.08%
+32.08%
1 Month
+28.01%
+28.01%
3 Month
+30.20%
+30.20%
6 Month
+59.79%
+59.79%
1 Year
+106.79%
+106.79%
More News
Read More
These stocks are gapping in today's session
March 06, 2025
Via
Chartmill
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
March 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Earnings Outlook For Xeris Biopharma Holdings
November 07, 2024
Via
Benzinga
Earnings Scheduled For March 6, 2025
March 06, 2025
Via
Benzinga
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
February 27, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
February 24, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Upcoming Investor Conferences
February 05, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Xeris Biopharma
Via
Business Wire
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
November 11, 2024
Via
Benzinga
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Upcoming Investor Conferences
August 22, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
August 14, 2024
Via
Benzinga
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
August 13, 2024
Via
Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.